Thailand and Turkey have standardized the use of a TEOAE + ABR protocol, while Japan and Taiwan additionally integrate genetic testing (e.g., GJB2, SLC26A4) to identify infants at risk for progressive or late-onset HL. Here, GJB2 is linked to Hodgkins lymphoma.